Marie Longo, Wendy Wickes, Matthew Smout, Sonia Harrison, Sharon Cahill, Jason M. White
31 May 2009
This study tested the impact of a long-acting form of amphetamine as medication to help control dependent use of the closely allied stimulant, methamphetamine. Prescribed usually for the treatment of pathological sleepiness or attention deficit/hyperactivity disorder, effects of the amphetamine tablets prescribed in the study take several hours longer to emerge than normal amphetamine and last three to six hours longer, giving it a 'smoothing' profile similar to methadone for heroin users; non-rapid onset make it less intensely pleasurable, and longer duration suits it to once-daily administration.
As a participant at last week’s 19th International HIV/AIDS Conference, I was reminded of President Fernando Henrique Cardoso’s and UNDP Administrator Helen Clark’s call to arms earlier in July that there is a new prescription for the AIDS response: ‘courage is needed’.